Edwards Capital Surpluse from 2010 to 2025

EW Stock  USD 71.35  0.89  1.26%   
Edwards Lifesciences Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 1.2 B in 2025. During the period from 2010 to 2025, Edwards Lifesciences Capital Surpluse regression line of quarterly data had mean square error of 80275.9 T and geometric mean of  1,018,713,664. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-06-30
Previous Quarter
2.1 B
Current Value
2.2 B
Quarterly Volatility
560.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 92.8 M, Interest Expense of 11 M or Selling General Administrative of 1.9 B, as well as many indicators such as Price To Sales Ratio of 4.44, Dividend Yield of 0.0 or PTB Ratio of 4.78. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Edwards Lifesciences Corp over the last few years. It is Edwards Lifesciences' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Edwards Capital Surpluse Regression Statistics

Arithmetic Mean1,210,097,476
Geometric Mean1,018,713,664
Coefficient Of Variation50.39
Mean Deviation484,851,584
Median1,180,164,615
Standard Deviation609,792,761
Sample Variance371847.2T
Range2.1B
R-Value0.89
Mean Square Error80275.9T
R-Squared0.80
Slope114,453,242
Total Sum of Squares5577708.2T

Edwards Capital Surpluse History

20251.2 B
20242.3 B
2022B
20211.7 B
20201.4 B
20191.6 B
20181.4 B

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse2.3 B1.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.